Pemfexy™ (pemetrexed) – New indication
December 19, 2022 - Eagle Pharmaceuticals announced the FDA approval of Pemfexy (pemetrexed), in combination with Keytruda® (pembrolizumab) and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Top